Added molecules included proteins for targeting (e.g., PTGFRN, NCT04592484), proteins for therapeutic effect (e.g., super‐repressor IκBα, NCT05843799), nucleic acids for therapeutic effect (e.g., miRNA‐124, NCT03384433), and other chemicals for therapeutic effect (e.g., curcumin, NCT01294072) In addition, one study utilized EVs from chimeric cells produced from fusing patient tumour cells with antigen presenting cells (NCT05559177). This evidence concerns the gene PTGFRN and neoplasm.